{"entity":{"id":"nct07146230","kind":"trial","name":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","aka":["SPRINT 2"],"tldr":"A phase 2 trial of durvalumab, monalizumab and oleclumab in lung cancer, run by Montefiore Medical Center, not yet recruiting.","summary":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 is a phase 2, randomised interventional study registered as NCT07146230 by Montefiore Medical Center, with a registry enrolment figure of 52 participants, started 2026-09 and due to reach its primary completion in 2028-04. Interventions recorded: Durvalumab; Monalizumab; Oleclumab; Radiotherapy. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Response rate observed using FDG-PET imaging. Lung eligibility wording from the registry: \"Previously untreated, pathologically proven NSCLC and one of the following stages:\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07146230","url":"https://clinicaltrials.gov/study/NCT07146230"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["stage-iii-unresectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":["durvalumab","monalizumab","oleclumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07146230","phase":"2","setting":"The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial 2 (SPRINT 2)","sponsor":"Montefiore Medical Center","enrolled":52,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07146230/","neighbours":{"cancer":[{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"monalizumab","kind":"drug","name":"Monalizumab","route":"/drugs/monalizumab/"},{"id":"oleclumab","kind":"drug","name":"Oleclumab","route":"/drugs/oleclumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}